Advances company’s ambition to provide fully integrated and comprehensive solution for viral vector manufacturing Mirus Bio’s leading GMP transfection reagents complement company’s upstream ...
MilliporeSigma operators monitoring viral vector production in a bioreactor. Submitted photo. Subscribe to BizTimes Daily – Local news about the people, companies and issues that impact business in ...
MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, announced the signing of a definitive agreement to acquire Mirus Bio for $600 million. This deal is ...
MilliporeSigma, the U.S. and Canada life science business of Germany-based Merck KGaA, closed the transaction to acquire Mirus Bio for approximately $600 million (around €550 million). The acquisition ...
ST. LOUIS--(BUSINESS WIRE)--MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, a leading science and technology company, has signed a non-binding Memorandum ...
Mirus Bio’s transfection reagents strengthen MilliporeSigma’s upstream portfolio Acquisition will advance company’s ambition to provide a fully integrated and comprehensive solution for viral vector ...
BURLINGTON, Mass. — MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, today announced that the company’s Life Science business has closed the transaction to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback